KYNVITAR Trademark
Trademark Overview
On Friday, July 7, 2023, a trademark application was filed for KYNVITAR with the United States Patent and Trademark Office. The USPTO has given the KYNVITAR trademark a serial number of 98074674. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, December 20, 2024. This trademark is owned by Novartis AG. The KYNVITAR trademark is filed in the Pharmaceutical Products category with the following description:
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the p...
General Information
| Serial Number | 98074674 |
| Word Mark | KYNVITAR |
| Filing Date | Friday, July 7, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Friday, December 20, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 30, 2024 |
Trademark Statements
| Goods and Services | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma; all of the above excluding pharmaceutical preparations for the treatment of adenosine deaminase deficiency called SCID-ADA |
| Translation of Words in Mark | The wording "KYNVITAR" has no meaning in a foreign language. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, August 7, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Novartis AG |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Basel 4002
CH |
| Party Name | Novartis AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Basel 4002
CH |
Trademark Events
| Event Date | Event Description |
| Tuesday, July 11, 2023 | NEW APPLICATION ENTERED |
| Monday, August 7, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 15, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, March 26, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 30, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 25, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, December 20, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, December 20, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, December 20, 2024 | SOU EXTENSION 1 FILED |
| Friday, December 20, 2024 | SOU EXTENSION 1 GRANTED |
